Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
SOPH SOPHiA Genetics SA
- Stocks
- Healthcare
- NASDAQ: SOPH
Price (delayed)
$3
Market cap
$200.46M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1
Enterprise value
$162.07M
sophia genetics, world's largest clinical genomics community, brings together expertise in genetics, bioinformatics, machine learning and genomic privacy. based in switzerland, we are known for our high medical standards and
Highlights
SOPH's gross profit is up by 4.9% year-on-year and by 4.1% since the previous quarter
SOPHiA Genetics's revenue has increased by 4.7% YoY and by 3.1% QoQ
SOPHiA Genetics's EPS has increased by 11% YoY but it has decreased by 5% from the previous quarter
The net income has grown by 9% YoY but it has contracted by 6% from the previous quarter
SOPHiA Genetics's debt has surged by 73% YoY
SOPH's equity is down by 35% year-on-year and by 11% since the previous quarter
Key stats
What are the main financial stats of SOPH
Market
Valuations
Earnings
Shares outstanding
66.82M
Market cap
$200.46M
Enterprise value
$162.07M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.34
Price to sales (P/S)
2.98
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.41
Revenue
$67.17M
Gross profit
$45.74M
Operating income
-$63.85M
Net income
-$66.17M
EBIT
-$63.42M
EBITDA
-$54.59M
Free cash flow
-$40.19M
Per share
Balance sheet
Liquidity
EPS
-$1
EPS diluted
-$1
Free cash flow per share
-$0.6
Book value per share
$1.28
Revenue per share
$1.01
TBVPS
$1.75
Total assets
$146.72M
Total liabilities
$61.11M
Debt
$30.13M
Equity
$85.61M
Working capital
$61.11M
Debt to equity
0.35
Current ratio
3.11
Quick ratio
2.74
Net debt/EBITDA
0.7
Margins
Efficiency
Dividend
EBITDA margin
-81.3%
Gross margin
68.1%
Net margin
-98.5%
Operating margin
-95.1%
Return on assets
-40.1%
Return on equity
-63.5%
Return on invested capital
-126.4%
Return on capital employed
-53.9%
Return on sales
-94.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SOPH stock price
How has the SOPHiA Genetics stock price performed over time
Intraday
-0.83%
1 week
4.53%
1 month
-0.99%
1 year
-40%
YTD
-2.28%
QTD
-9.64%
Financial performance
How have SOPHiA Genetics's revenue and profit performed over time
Revenue
$67.17M
Gross profit
$45.74M
Operating income
-$63.85M
Net income
-$66.17M
Gross margin
68.1%
Net margin
-98.5%
The operating margin has grown by 18% YoY and by 7% from the previous quarter
SOPH's operating income is up by 14% YoY and by 4.1% from the previous quarter
SOPHiA Genetics's net margin has increased by 13% YoY but it has decreased by 2.7% QoQ
The net income has grown by 9% YoY but it has contracted by 6% from the previous quarter
Price vs fundamentals
How does SOPH's price correlate with its fundamentals
Growth
What is SOPHiA Genetics's growth rate over time
Valuation
What is SOPHiA Genetics stock price valuation
P/E
N/A
P/B
2.34
P/S
2.98
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.41
SOPHiA Genetics's EPS has increased by 11% YoY but it has decreased by 5% from the previous quarter
SOPH's equity is down by 35% year-on-year and by 11% since the previous quarter
The P/S is 19% below the last 4 quarters average of 3.7
SOPHiA Genetics's revenue has increased by 4.7% YoY and by 3.1% QoQ
Efficiency
How efficient is SOPHiA Genetics business performance
SOPHiA Genetics's ROE has decreased by 33% YoY and by 18% from the previous quarter
The ROIC has grown by 32% YoY
SOPHiA Genetics's ROS has increased by 16% YoY but it has decreased by 3.6% from the previous quarter
The ROA has declined by 12% year-on-year and by 11% since the previous quarter
Dividends
What is SOPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SOPH.
Financial health
How did SOPHiA Genetics financials performed over time
SOPH's total assets is 140% greater than its total liabilities
The company's quick ratio fell by 28% YoY and by 16% QoQ
The total liabilities has grown by 27% YoY and by 3.9% from the previous quarter
SOPHiA Genetics's debt is 65% lower than its equity
The debt to equity has soared by 169% year-on-year and by 13% since the previous quarter
SOPHiA Genetics's debt has surged by 73% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.